Payment overview · 2025
General Payments
$823.61
54 reported records · 11 companies
Healthcare provider profile · identity verified
Fernando Alemany, M.D.,
Allopathic & Osteopathic Physicians|Internal Medicine · OPELOUSAS, LA · NPI 1003990656
Verified facts
What the public records show
CMS Open Payments records show Fernando Alemany, M.D., received $823.61 in general payments during 2025 across 54 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Synthroid, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DELSTRIGO as an associated drug or biological on 864 records involving 608 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Delstrigo by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Isentress by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $203.75 | 24.7% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $173.23 | 21.0% | 16 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $118.42 | 14.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.15 | 9.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.01 | 7.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $54.40 | 6.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $44.76 | 5.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.29 | 4.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.64 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.02 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.94 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $823.61 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $184.64 | 17 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $118.42 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.32 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $67.56 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.01 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $54.40 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $49.89 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $44.76 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $40.30 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $10.02 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $10.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 116 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 163 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 150 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
116 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
150 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
163 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | DELSTRIGO open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 608 recipient NPIs · example record 1237993240 |
Delstrigo · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 629 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 524 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 522 | 130 |
| Gabapentin | Gabapentin | 438 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 425 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 423 | 82 |
| Metformin Hcl | Metformin Hcl | 369 | 75 |
| Furosemide | Furosemide | 337 | 63 |
| Simvastatin | Simvastatin | 302 | 68 |
| Potassium Chloride | Potassium Chloride | 289 | 52 |
| Benazepril Hcl | Benazepril Hcl | 284 | 62 |
| Omeprazole | Omeprazole | 271 | 52 |
| Trazodone Hcl | Trazodone Hcl | 270 | 64 |
| Lisinopril | Lisinopril | 230 | 42 |
| Eliquis | Apixaban | 216 | 31 |
| Carvedilol | Carvedilol | 208 | 46 |
| Alprazolam | Alprazolam | 207 | 28 |
| Allopurinol | Allopurinol | 202 | 55 |
| Montelukast Sodium | Montelukast Sodium | 199 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 196 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 44 |
| Losartan Potassium | Losartan Potassium | 188 | 41 |
| Colchicine | Colchicine | 182 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 32 |
| Zafirlukast | Zafirlukast | 175 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 170 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 35 |
| Cefdinir | Cefdinir | 166 | 112 |
| Dexamethasone | Dexamethasone | 165 | 113 |
| Ozempic | Semaglutide | 164 | 33 |
| Mounjaro | Tirzepatide | 163 | 31 |
| Mirtazapine | Mirtazapine | 154 | 20 |
| Januvia | Sitagliptin Phosphate | 152 | 22 |
| Buspirone Hcl | Buspirone Hcl | 151 | 37 |
| Synthroid | Levothyroxine Sodium | 150 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 147 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 141 | 29 |
| Glyxambi | Empagliflozin/Linagliptin | 138 | 21 |
| Meloxicam | Meloxicam | 136 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 132 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 17 |
| Sertraline Hcl | Sertraline Hcl | 121 | 26 |
| Alendronate Sodium | Alendronate Sodium | 120 | 29 |
| Linzess | Linaclotide | 116 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 116 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 115 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 21 |
| Nifedipine Er | Nifedipine | 111 | 27 |
| Fenofibrate | Fenofibrate | 102 | 25 |
| Pregabalin | Pregabalin | 102 | 17 |
| Tramadol Hcl | Tramadol Hcl | 101 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 16 |
| Celecoxib | Celecoxib | 95 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 33 |
| Fenofibrate | Fenofibrate Nanocrystallized | 94 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 12 |
| Memantine Hcl | Memantine Hcl | 87 | 20 |
| Spironolactone | Spironolactone | 87 | 22 |
| Xarelto | Rivaroxaban | 84 | 18 |
| Ramipril | Ramipril | 81 | 18 |
| Sucralfate | Sucralfate | 78 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 77 | 51 |
| Glimepiride | Glimepiride | 76 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 32 |
| Valsartan | Valsartan | 69 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 12 |
| Donepezil Hcl | Donepezil Hcl | 66 | 18 |
| Azithromycin | Azithromycin | 65 | 50 |
| Rybelsus | Semaglutide | 62 | 18 |
| Irbesartan | Irbesartan | 61 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 61 | 12 |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 60 | suppressed |
| Prednisone | Prednisone | 60 | 43 |
| Diltiazem 24hr Er | Diltiazem Hcl | 57 | 14 |
| Febuxostat | Febuxostat | 57 | 13 |
| Trulicity | Dulaglutide | 56 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 54 | suppressed |
| Ondansetron Odt | Ondansetron | 52 | 16 |
| Fluconazole | Fluconazole | 51 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 12 |
| Lovastatin | Lovastatin | 50 | 12 |
| Baclofen | Baclofen | 49 | suppressed |
| Finasteride | Finasteride | 49 | 15 |
| Fenofibrate | Fenofibrate,micronized | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 46 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 14 |
| Jardiance | Empagliflozin | 42 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 34 |
| Xifaxan | Rifaximin | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Famotidine | Famotidine | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | 13 |
| Meclizine Hcl | Meclizine Hcl | 40 | 11 |
| Megestrol Acetate | Megestrol Acetate | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 34 |
| Risperidone | Risperidone | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 22 |
| Estradiol | Estradiol | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 30 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Lactulose | Lactulose | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Mupirocin | Mupirocin | 33 | 24 |
| Olanzapine | Olanzapine | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 16 |
| Temazepam | Temazepam | 30 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 28 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Nystatin | Nystatin | 25 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Isentress | Raltegravir Potassium | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 14 |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Tiadylt Er | Diltiazem Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Isentress Hd | Raltegravir Potassium | 17 | suppressed |
| Quviviq | Daridorexant Hcl | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Efavirenz | Efavirenz | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Stribild | Elviteg/Cob/Emtri/Tenofo Disop | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $823.61 · 54 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | CAPLYTA, CAPVAXIVE, CREON, Cologuard Collection Kit, IBSRELA, JARDIANCE, Korlym, LINZESS, MOUNJARO, OTEZLA, PIFELTRO, RELISTOR, SYNTHROID, UBRELVY, VIBERZI, VRAYLAR, XIFAXAN, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error